DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
506943 logo

J. B. Chemicals & Pharmaceuticals Limited Stock Price

BSE:506943 Community·₹387.3b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

506943 Share Price Performance

₹2,412.25
691.70 (40.20%)
​
₹2,258.22
Fair Value
₹2,412.25
691.70 (40.20%)
6.8% overvalued intrinsic discount
₹2,258.22
Fair Value
Price ₹2,412.25
AnalystConsensusTarget ₹2,258.22
Thu, 4 Jun 26
Fair Value₹2,258.22
Share Pricen/a

506943 Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value ₹2.26k 6.8% overvalued intrinsic discount

Chronic Therapeutic Demand And CDMO Launches Will Extend Global Reach

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
506943 logo
J. B. Chemicals & Pharmaceuticals
6.8% overvalued intrinsic discount

Chronic Therapeutic Demand And CDMO Launches Will Extend Global Reach

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 4 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
506943 logo

506943: Dividend Decision And Margin Outlook Will Shape A Steady Future

Fair Value: ₹2.26k 6.8% overvalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with high growth potential and pays a dividend.

2 Risks
2 Rewards
View Full Analysis

J. B. Chemicals & Pharmaceuticals Limited Key Details

₹41.5b

Revenue

₹13.4b

Cost of Revenue

₹28.1b

Gross Profit

₹21.0b

Other Expenses

₹7.1b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
44.19
67.77%
17.10%
0%
View Full Analysis

About 506943

Founded
1976
Employees
5602
CEO
n/a
WebsiteView website
www.jbpharma.com

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Recent 506943 News & Updates

User avatar
Narrative Update • Jun 04

506943: Dividend Decision And Margin Outlook Will Shape A Steady Future

Analysts have inched up their price target for J. B.

Recent updates

No updates

J. B. Chemicals & Pharmaceuticals Limited Competitors

SUNPHARMA logo

Sun Pharmaceutical Industries

Symbol: NSEI:SUNPHARMA
Market cap: ₹4.4t
DIVISLAB logo

Divi's Laboratories

Symbol: NSEI:DIVISLAB
Market cap: ₹2.5t
500420 logo

Torrent Pharmaceuticals

Symbol: BSE:500420
Market cap: ₹1.8t
ZYDUSLIFE logo

Zydus Lifesciences

Symbol: NSEI:ZYDUSLIFE
Market cap: ₹1.2t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide